GnuBIO Promotes Susie Truong Harborth to Key Role as Chief Financial Officer

As GnuBIO Prepares for Commercialization of Its Desktop DNA Sequencer, Susie Harborth is Promoted to Chief Financial Officer

GnuBIO, Inc.Jessica Tonani, 617-446-6744

, Inc., a pioneer in desktop DNA sequencing, today announced that Susie Truong Harborth has been promoted to Chief Financial Officer. Ms. Harborth has been with GnuBIO, since the company’s inception and will continue to lead finance, human resources and operations of the company while taking on new responsibilities for company strategy.

Ms. Harborth is a strategic financial and operations executive with a strong track record launching and managing life science companies. She has held senior management positions at Cequent Pharmaceuticals (acquired by Marina Biotech) and built the initial infrastructure for Boston Heart Diagnostics (BHDx). Ms. Harborth is also co-founder of BioInnovation LLC, a provider of capital and services to life science companies and is an advisor to ventures in software, consumer products and financial services. Prior to senior level roles at leading venture-backed companies, Ms. Harborth was at Leerink Swann & Co, a boutique investment bank for life science companies.

" has the unique combination of world-class talent and innovative DNA sequencing technology. Susie is a key member of our management team and continues to make significant contributions in leading our company through our rapid growth and expansion. She is instrumental to our success and in her expanded role, will continue to execute on our strategic direction as the company prepares for commercialization in 2013,” states John Boyce, co-founder, president and CEO of GnuBIO.

"It has been such an honor to work with the entire GnuBIO, , team and I am excited at the next phase of the company’s growth,” stated Harborth. “As we look towards commercialization and building up the company to become a leading DNA sequencing platform, from targeted sequencing to whole genomes, we will continue to build upon our innovation and bring on more talent.”

About GnuBIO: () is a privately-held company developing next-generation desktop DNA sequencing technology that will compartmentalize the entire DNA sequencing process, combining all of the steps required for sequencing in a single system, and providing the only fully integrated next-generation sequencing workflow. The sequencing technology is based on an emulsion based microfluidic technology which also provides a scalable sequencing solution that allows for interrogation of single genes, gene panels or whole genomes. The user of his GnuBIO system simply injects the patient sample into the cartridge, the appropriate panel is run – inclusive of gene capture, PCR, sequencing, and informatics analysis – and the results are ready within hours. Unlike any other DNA sequencing system, the entire process is all on the chip, simplifying the complex sample preparation process and breaking the barrier of an obstacle that has prevented the widespread adoption of DNA sequencing.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.